Cynthia M Stonnington1,2, Yinghua Chen3,2, Cary R Savage3,2, Wendy Lee3,2, Robert J Bauer3,2, Sameen Sharieff1,4,2, Pradeep Thiyyagura3,2, Gene E Alexander5,6,2, Richard J Caselli7,2, Dona E C Locke1,2, Eric M Reiman3,8,9,2, Kewei Chen3,10,9,2. 1. Department of Psychiatry and Psychology, Mayo Clinic Arizona, Scottsdale, AZ, USA. 2. Arizona Alzheimer's Consortium, Phoenix, AZ, USA. 3. Banner Alzheimer's Institute and Banner Good Samaritan PET Center, Phoenix, AZ, USA. 4. Midwestern University, Glendale, AZ, USA. 5. Department of Psychology and Evelyn F. McKnight Brain Institute, University of Arizona, Tucson, AZ, USA. 6. Neuroscience and Physiological Science Interdisciplinary Graduate Programs, University of Arizona, Tucson, AZ, USA. 7. Department of Neurology, Mayo Clinic Arizona, Scottsdale, AZ, USA. 8. Translational Genomics Research Institute, Scottsdale, AZ, USA. 9. Department of Psychiatry, University of Arizona, Tucson, AZ, USA. 10. Arizona State University, Tempe, AZ, USA.
Abstract
BACKGROUND: Brain imaging measurements can provide evidence of possible preclinical Alzheimer's disease (AD). Their ability to predict individual imminent clinical conversion remains unclear. OBJECTIVE: To investigate the ability of pre-specified volumetric magnetic resonance imaging (MRI) and fluorodeoxyglucose positron emission tomography (FDG-PET) measurements to predict which cognitively unimpaired older participants would subsequently progress to amnestic mild cognitive impairment (aMCI) within 2 years. METHODS: From an apolipoprotein E4 (APOE4) enriched prospective cohort study, 18 participants subsequently progressed to the clinical diagnosis of aMCI or probable AD dementia within 1.8±0.8 years (progressors); 20 participants matched for sex, age, education, and APOE allele dose remained cognitively unimpaired for at least 4 years (nonprogressors). A complementary control group not matched for APOE allele dose included 35 nonprogressors. Groups were compared on baseline FDG-PET and MRI measures known to be preferentially affected in the preclinical and clinical stages of AD and by voxel-wise differences in regional gray matter volume and glucose metabolism. Receiver Operating Characteristic, binary logistic regression, and leave-one-out procedures were used to predict clinical outcome for the a priori measures. RESULTS: Compared to non-progressors and regardless of APOE-matching, progressors had significantly reduced baseline MRI and PET measurements in brain regions preferentially affected by AD and reduced hippocampal volume was the strongest predictor of an individual's imminent progression to clinically significant memory decline (79% sensitivity/78% specificity among APOE-matched cohorts). CONCLUSION: Regional MRI and FDG-PET measurements may be useful in predicting imminent progression to clinically significant memory decline.
BACKGROUND: Brain imaging measurements can provide evidence of possible preclinical Alzheimer's disease (AD). Their ability to predict individual imminent clinical conversion remains unclear. OBJECTIVE: To investigate the ability of pre-specified volumetric magnetic resonance imaging (MRI) and fluorodeoxyglucose positron emission tomography (FDG-PET) measurements to predict which cognitively unimpaired older participants would subsequently progress to amnestic mild cognitive impairment (aMCI) within 2 years. METHODS: From an apolipoprotein E4 (APOE4) enriched prospective cohort study, 18 participants subsequently progressed to the clinical diagnosis of aMCI or probable AD dementia within 1.8±0.8 years (progressors); 20 participants matched for sex, age, education, and APOE allele dose remained cognitively unimpaired for at least 4 years (nonprogressors). A complementary control group not matched for APOE allele dose included 35 nonprogressors. Groups were compared on baseline FDG-PET and MRI measures known to be preferentially affected in the preclinical and clinical stages of AD and by voxel-wise differences in regional gray matter volume and glucose metabolism. Receiver Operating Characteristic, binary logistic regression, and leave-one-out procedures were used to predict clinical outcome for the a priori measures. RESULTS: Compared to non-progressors and regardless of APOE-matching, progressors had significantly reduced baseline MRI and PET measurements in brain regions preferentially affected by AD and reduced hippocampal volume was the strongest predictor of an individual's imminent progression to clinically significant memory decline (79% sensitivity/78% specificity among APOE-matched cohorts). CONCLUSION: Regional MRI and FDG-PET measurements may be useful in predicting imminent progression to clinically significant memory decline.
Authors: N Tzourio-Mazoyer; B Landeau; D Papathanassiou; F Crivello; O Etard; N Delcroix; B Mazoyer; M Joliot Journal: Neuroimage Date: 2002-01 Impact factor: 6.556
Authors: M J de Leon; A Convit; O T Wolf; C Y Tarshish; S DeSanti; H Rusinek; W Tsui; E Kandil; A J Scherer; A Roche; A Imossi; E Thorn; M Bobinski; C Caraos; P Lesbre; D Schlyer; J Poirier; B Reisberg; J Fowler Journal: Proc Natl Acad Sci U S A Date: 2001-08-28 Impact factor: 11.205
Authors: C R Jack; R C Petersen; Y C Xu; P C O'Brien; G E Smith; R J Ivnik; B F Boeve; S C Waring; E G Tangalos; E Kokmen Journal: Neurology Date: 1999-04-22 Impact factor: 9.910
Authors: C R Jack; R C Petersen; Y Xu; P C O'Brien; G E Smith; R J Ivnik; B F Boeve; E G Tangalos; E Kokmen Journal: Neurology Date: 2000-08-22 Impact factor: 9.910
Authors: Eric M Reiman; Kewei Chen; Gene E Alexander; Richard J Caselli; Daniel Bandy; David Osborne; Ann M Saunders; John Hardy Journal: Proc Natl Acad Sci U S A Date: 2003-12-19 Impact factor: 11.205
Authors: Henry Rusinek; Susan De Santi; Dina Frid; Wai-Hon Tsui; Chaim Y Tarshish; Antonio Convit; Mony J de Leon Journal: Radiology Date: 2003-12 Impact factor: 11.105
Authors: Margaret Abraham; Michael Seidenberg; Dana A Kelly; Kristy A Nielson; John L Woodard; J Carson Smith; Sally Durgerian; Stephen M Rao Journal: J Int Neuropsychol Soc Date: 2020-03-05 Impact factor: 2.892
Authors: Qunxi Dong; Wen Zhang; Cynthia M Stonnington; Jianfeng Wu; Boris A Gutman; Kewei Chen; Yi Su; Leslie C Baxter; Paul M Thompson; Eric M Reiman; Richard J Caselli; Yalin Wang Journal: Neuroimage Clin Date: 2020-07-05 Impact factor: 4.881
Authors: Allison Hansen; Richard J Caselli; Gretchen Schlosser-Covell; Michael A Golafshar; Amylou C Dueck; Bryan K Woodruff; Cynthia M Stonnington; Yonas E Geda; Dona E C Locke Journal: Alzheimers Dement (Amst) Date: 2018-09-27